← Leaderboards
Joshua Canzoneri
Adt Pharmaceuticals, Llc
$413,440
Attributed
$826,879
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $300K · FY2015–18$500K$375K$250K$125K$0
'15
'16
'17
'18
Funding mix
By agency
NIH$826,879 · 3
By mechanism
R43$826,879 · 3
Top collaborators
- Michael R Boyd2 shared
- Gary A Piazza2 shared
Most similar at Adt Pharmaceuticals, Llc
Same institution · by research overlap
- Michael R Boyd$151,000
Others in their field
Top investigators on “Pharmacologic Substance”
- David Heimbrook · Leidos Biomedical Research, Inc.$127,683,054
- Myron S Cohen · Family Health International$104,232,876
- Wafaa M. El-Sadr · Columbia University Health Sciences$104,068,526
- Garret A Fitzgerald · University Of Pennsylvania$73,814,804
- James Dennis Neaton · Northwestern University$65,107,995
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$53,206,876
Research focus
Pharmacologic SubstanceSeriesMalignant NeoplasmsPharmaceutical PreparationsPlasmaScreeningLeadMalignant Neoplasm Of LungMedicalOralDrug KineticsIn VivoPropertyScale UpGrowthCellsChemotherapyLung NeoplasmsClinical TrialsDoseMouse ModelNeoplastic CellBaseSignal Transduction
Grant awards (4)
Oral formulation for novel inhibitor of Ras driven cancers$2,000
R43 · FY2018 · CA · contact PI
Oral formulation for novel inhibitor of Ras driven cancers$300,000
R43 · FY2017 · CA · contact PI
Novel Ras inhibitor prodrug for colorectal cancer$300,000
R43 · FY2016 · CA · contact PI
A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer$224,879
R43 · FY2015 · CA · contact PI